Navigation Links
Drug Therapy Offers Little Benefit for Some Patients Undergoing Angioplasty or Stent Procedure

rs found that there was no difference in the rate of death at 30 days between placebo and pexelizumab treated patients, i.e., each experiencing a low death rate of 3.92 percent and 4.06 percent, respectively. The 30-day composite end point of death, cardiac shock, or heart failure was also similar between treatment groups (9.19 percent for placebo and 8.99 percent with pexelizumab). At 90 days death remained low and similar in both treatment groups, i.e., 4.51 percent and 4.93 percent for placebo and pexelizumab, respectively. The composite end point of death, shock, or heart failure was also similar at day 90.

‘It remains unclear whether other myocardial protection strategies including anti-inflammatory, antiapoptotic [prevention of cell death], or metabolic manipulation might be successful. Whereas a proinflammatory state relates to worse outcomes, and we have previously shown that it can be modified by pexelizumab the extent to which inflammation is caused by vs. contributes to myocardial damage is unknown. Timing of administration of therapies and targeting high-risk patients most likely to benefit are likely important variables in the modulation of inflammation in the clinical setting. The lack of benefit of pexelizumab in APEX underscores the challenge of translating promising experimental treatments for myocardial protection to the clinic,' the authors write.

Source-JAMA
'"/>




Page: 1 2

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
(Date:3/27/2015)... Alberta (PRWEB) March 27, 2015 In her ... then, prevented her from working, Monica K. arrived at ... the mending department quiet, defensive and scared. The owners and ... & Support Services (EPSS) to offer jobs to challenged ... take patience and a willingness to begin with the end ...
(Date:3/27/2015)... March 27, 2015 First Choice Emergency ... The new facility is located 12665 W Lake Houston Pkwy, ... resident of Summerwood, I look forward to delivering the highest ... Sowell, Facility Medical Director of First Choice Emergency Room Summerwood. ... Room made a donation to Summer Creek High School at ...
(Date:3/27/2015)... Healthpointe is proud to announce that ... now treating knee and hip joint disorders in practice ... Beach, and La Mirada. Dr. Stanley Katz specializes in ... joint disorders as well as chronic conditions such as ... his patients back to their normal lives. Many ...
(Date:3/27/2015)... 2015 The report “CountryFocus Healthcare, ... essential source of information on and analysis of ... Germany’s increasingly elderly population and its associated disease ... In 2013, the elderly accounted for 27.1% of ... Annual Growth Rate (CAGR) of 1.2% to 29.5% ...
(Date:3/27/2015)... According to a recently published report series ... screw market in Europe is in decline due to ... segment. Price decreases are being seen across the entire ... the total European trauma device market, continued pricing pressure ... year after year. , “Such price drops are ...
Breaking Medicine News(10 mins):Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3
... geneticist at the University of Edinburgh, Scotland, had announced on ... called Uqcrc1 in the brains of mouse used as models ... powerhouses of the cells to work overtime. Dr. Bird stated ... been linked to Rett Syndrome. The co-author of the study ...
... that the male survivors of childhood sexual abuse ... understood// many health care practitioners as well as ... male and female childhood sexual survivors usually exhibit ... encounters with health care professionals, there are gender ...
... Mental health experts have said that New Orleans seems ... post-traumatic stress// disorder of an intensity rarely seen in ... that existed before hurricane Katrina struck, 10 months ago. ... has almost collapsed completely leaving the police department to ...
... Celiac Sprue Research Foundation have claimed to discover a ... is an inherited inflammatory disorder of the small intestine ... The two research studies that have been published in ... the way for clinical testing with an oral enzyme ...
... recalled almost around 20,000 chocolate bars in Britain as ... bars may contain traces of salmonella. ,A ... minute traces of salmonella, which though quite are significantly ... for any hazards. The spokesperson had also clarified that ...
... announced their plans to use a protein that has been ... ice creams using genetically// modified technology. ,The parent ... them to develop ice creams that are of low-calorie, and ... technology to make newer versions of their best selling products ...
Cached Medicine News:Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 2Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 3Health News:Sexually Abused Males Found Struggling In heir relations with Healthcare Providers 2Health News:Scientists Discover Non-dietary Therapy For Celiac Diseases 2Health News:Wall's To Develop Low-fat Ice-cream Using Fish Blood 2
(Date:3/27/2015)... 27, 2015 According to a ... Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), ... (AF, VT, WPW) - Global Forecasts to 2019 ", published ... reach around ~$4.73 Billion by 2019 with a CAGR ... 2019. Browse   90   ma ...
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
(Date:3/27/2015)... 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... today announced that they have entered into ... and proprietary sd-rxRNA® technology for use in ... has the potential to result in novel, ... that could be a significant step toward ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... pirfenidone may provide meaningful clinical benefit in IPF patients ... reported -- Conference Call and Webcast at 9 p.m. ... InterMune, Inc. (Nasdaq: ITMN ) reported ... evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) ...
... 19 New data demonstrate that maintenance therapy with ... time to relapse compared to placebo in patients with ... this week at a major medical meeting. Bipolar ... in a person,s mood, energy and ability to function. ...
Cached Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
... All of DOA Panel Test ... step in vitro test. It ... drug substances in human urine ... evaluated in the point of ...
... is an immunochromatography based one step ... qualitative determination of amphetamine in human ... 1000 ng/mL. This assay has not ... care,location and is for use by ...
... fully automated, user-friendly system that helps ... and improve patient care. This state-of-the-art ... testing capabilities with a complete menu ... also a powerful, intuitive system that ...
... in-vitro diagnostic test kit for the ... in human serum/plasma. This test is ... gelatin particles coated with inactivated Trypanosoma ... are agglutinated in the presence of ...
Medicine Products: